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The amiloride-sensitive epithelial sodium channel (ENaC)
constitutes a limiting step in sodium reabsorption across distal
airway epithelium and controllingmucociliary clearance. ENaC
is activated by serine proteases secreted in the extracellular
milieu. In cystic fibrosis lungs, high concentrations of secreted
neutrophil elastase (NE) are observed. hNE could activate ENaC
and contribute to further decreased mucociliary clearance. The
aims of this study were (i) to test the ability of an engineered
human neutrophil elastase inhibitor (EPI-hNE4) to specifically
inhibit the elastase activation of ENaC-mediated amiloride-sen-
sitive currents (INa) and (ii) to examine the effect of elastase on
cell surface expression of ENaC and its cleavage pattern (exoge-
nous proteolysis). Oocytes were exposed to hNE (10–100
g/ml) and/or trypsin (10g/ml) for 2–5min in the presence or
absence of EPI-hNE4 (0.7 M). hNE activated INa 3.6-fold
(p < 0.001) relative to non-treated hENaC-injected oocytes.
EPI-hNE4 fully inhibited hNE-activated INa but had no effect on
trypsin- or prostasin-activated INa. The co-activation of INa by
hNE and trypsin was not additive. Biotinylation experiments
revealed that cell surfaceENaC (but not orENaC) exposed
to hNE for 2 min was cleaved (as a 67-kDa fragment) and corre-
lated with increased INa. The elastase-induced exogenous pro-
teolysis pattern is distinct from the endogenous proteolysis pat-
tern induced upon preferential assembly, suggesting a causal
relationship between  ENaC cleavage and ENaC activation,
taking place at the plasma membrane.
The highly sodium-selective epithelial sodium channel
(ENaC)2 is composed of three homologous subunits (, , )
and is expressed in several ion-transporting epithelia, including
the kidney, colon, and lung (1). The physiological importance of
ENaC in the lungwas recognizedwhenENaCknock-outmice
were shown to die prematurely because of defective lung liquid
clearance (2), indicating ENaC as a major driving force for fluid
reabsorption from the alveolar space at the time of birth. Active
transepithelial sodium transport by surface airway epithelia
provides a major driving force for the control of airway surface
liquid and periciliar liquid (PCL), highly critical formucociliary
clearance (3, 4). ENaC, located at the apical membrane of the
surface airways epithelium (SAE), constitutes a limiting step for
sodiumabsorption by SAE, as shownbyhuman genetic diseases
(5). Thus, loss of function of ENaC, as observed in pseudohy-
poaldosteronism, leads to a 2–3-fold increase in mucociliary
clearance (6). By contrast, increased ENaC activity, secondary
to a loss of function of the cystic fibrosis transmembrane regu-
lator, is observed in cystic fibrosis (CF) patients. CF is a disease
that is characterized by mutation of the cystic fibrosis trans-
membrane regulator gene (7). The cystic fibrosis transmem-
brane regulator is responsible for Cl-driven fluid secretion in
upper and lower airways and inhibits antagonistic fluid absorp-
tion through ENaC (8, 9). CF patients thus experience a severe
decrease in mucociliary clearance (10). Mall et al. (11) have
recently established that increased ENaC expression and activ-
ity in airways of transgenic mice may cause per se a “cystic
fibrosis-like lung disease” characterized by decreasedmucocili-
ary clearance and tissue inflammation even in the absence of
microbial infection. Together, these findings suggest that over-
activity of ENaC contributes significantly to the CF phenotype.
Thus, ENaC becomes a valid drug target for treating CF
patients.
Numerous studies have shown that several serine proteases
are capable of increasing ENaC-mediated INa in multiple cell
types (12), including the in vitro and in vivo rodent lung (13–
15). The activation of ENaC by serine proteases may be a direct
consequence of proteolytic cleavage (16) by a dramatic change
in its open probability (Po) (17). Because over-activity of ENaC
is capable of inducing a CF-like phenotype, proteolytic activa-
tion of ENaC could be detrimental to CF patients.
The serine protease neutrophil elastase (hNE) has been
shown to reach concentrations 200 g/ml in the lungs of
patients with CF (21) and to overcome antiprotease activity
(19), whereas healthy subjects have undetectable levels of
hNE. The hNE in the lungs of patients with CF is known to
cause cellular damage, production of the pro-inflammatory
cytokine interleukin 8, and increased neutrophil influx (20) (21,
22). If hNE is also capable of activating ENaC, it would thereby
exacerbate the CF phenotype and actions taken to reduce this
activation could be beneficial to CF patients. Recently, Caldwell
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et al. (23) have shown that hNE is capable of stimulating INa in
a human bronchiole cell line and that an elastase inhibitor can
prevent elastase-mediated stimulation.
Elastase inhibitor therapy is currently being developed to
treat CF and chronic obstructive pulmonary disease by pre-
venting hNE-induced lesions in the pulmonary epithelium. In
this study, we have examined the effectiveness of one of these
compounds, EPI-hNE4, an engineered hNE inhibitor that was
designed to be a specific, high affinity drug, resistant to oxida-
tive and proteolytic inactivation.
We have hypothesized that hNE can cleave cell surface-ex-
pressed ENaC, which results in channel activation, and that
EPI-hNE4 can prevent this cleavage/activation. To identify
whether ENaCwas being directly cleaved by hNE, oocytes were
analyzed for increased ENaC-mediated INa and for proteolytic
cleavage of cell surface proteins. Here, we present data indicat-
ing that elastase is capable of activating ENaC, possibly by
cleaving cell surface-expressed  ENaC and that this effect can
be blocked by the elastase-specific inhibitor EPI-hNE4. The ela-
stase-induced cleavage (exogenous proteolysis) is distinct from
the cleavage pattern observed upon preferential assembly of ,
, and  ENaC subunits by oocyte proteases (endogenous pro-
teolysis), suggesting a causal relationship between cleavage and
ENaC activation.
EXPERIMENTAL PROCEDURES
cRNAs—Complementary RNAs of human or rat  ENaC
subunits and human prostasin were synthesized in vitro, using
SP6 and T7 polymerase. C terminus V5 epitope-tagged , ,
and  ENaC subunits were created by PCR amplification. For
each subunit, two primers were synthesized. The forward
primer contains the SpeI site and the start codon of the ENaC
gene; the reverse primer contains the NotI site, the coding
sequence for V5, and the C-terminal sequence of the ENaC
gene. PCR products were purified and cloned into the SpeI/
NotI sites of pSDE vector.
Antibodies—Monoclonal anti-V5 antibody was obtained
from Invitrogen and used according to the manufacturer’s
instruction. The actin antibody was from Sigma.
Expression of ENaC and Human Prostasin cRNA in Xenopus
oocytes—The cRNAs were injected into Xenopus oocytes (3.3
ng of each subunit and 3.3 ng of human CAP-1 (prostasin) 
13.2 ng of total cRNA/oocyte), and injected oocytes were kept
in modified Barth solution (MBS) containing 88 mM NaCl, 1
mM KCl, 2.4 mM NaHCO3, 0.8 mM MgSO4, 0.3 mM Ca(NO3)2,
0.4 mMCaCl2, 10mMHepes-NaOH, pH 7.2. Electrophysiologi-
cal measurements and cell surface biotinylation were per-
formed 24 h after injection. Amiloride-sensitive Na current
(INa) was recorded using the two-electrode voltage clamp and
was defined as the difference between Na current obtained in
the presence (5 M) and in the absence of amiloride.
Incubation of Xenopus oocytes with Proteases and Inhibitors—
ENaC-injected oocytes were incubated for 2 min at room tem-
perature in MBS solution containing proteases and/or inhibi-
tors. hNE from human neutrophils (Serva Electrophoresis) was
used at a concentration of 10–100 g/ml, trypsin (Sigma) was
used at a concentration of 10g/ml, engineered human elastase
inhibitor (Debiopharm SA) was used at a concentration of 4.4
g/ml, and aprotinin was used overnight at a concentration of
100 g/ml. At the end of the incubation, elastase inhibitors
were added to all samples before biotinylation.
Biotinylation of ENaC Subunits on the Cell Surface—Biotiny-
lation was performed in 40-well plates, using 50 oocytes/exper-
imental condition as described (24). All biotinylation stepswere
performed at 4 °C. After incubation inMBS solution for 30min
at 4 °C, the oocytes were washed three times with MBS. After
the last wash, theMBS solution was removed and replaced by a
biotinylation buffer containing 10mM triethanolamine, 150mM
NaCl, 2 mM CaCl2, 1 mg/ml EZ-link sulfo-NHS-SS-Biotin
(Pierce), pH 9.5. The incubation lasted 15 min with gentle agi-
tation. The biotinylation reaction was stopped by washing the
oocytes two times with Quench buffer containing 192 mM gly-
cine, 25 mM Tris-Cl, pH 7.5, added to MBS solution. After the
second wash, oocytes were incubated for 5 min in the Quench
buffer with gentle agitation. Oocytes were then washed two
times with MBS solution and lysed by repeated pipetting with
Pasteur pipettes in lysis buffer containing 1%Triton X-100, 500
mMNaCl, 5mM EDTA, 50mMTris-Cl, 5g/ml each of leupep-
tin, antipain, and pepstatin, 10 g/ml aprotinin, and 4.4 g/ml
EPI-hNE4 (20 l/oocyte). The lysates were vortexed for 30 s
and centrifuged for 10 min at 10,000  g. Supernatants
were transferred to the new 1.5-ml Eppendorf tubes contain-
ing 50 l of immunopure immobilized streptavidin beads
(Pierce) washed with lysis buffer. After overnight incubation at
4 °C with agitation, the tubes were centrifuged for 1 min at
5,000 rpm. Supernatant was removed, and beads were washed
three times with lysis buffer. 35 l of 2 SDS-PAGE sample
buffer was added to the beads. All samples were heated for 5
min at 95 °C before loading on the 8–15% SDS-PAGE.
RESULTS
The endogenous processing of ENaC in the Xenopus oocyte
expression system is significant and specific for each subunit.
Hughey et al. (16) have implicated furin in ENaC proteolytic
processing. It is not known if other enzymes are involved, and it
is not clearwhether this processing is related to the activation of
ENaC at the cell surface. The study of exogenous secreted ser-
ine proteases (trypsin, elastase) could help in understanding
whether ENaC cleavage is required for activation or not. We
coupled the use of hNE with a highly specific inhibitor to study
the relationship between cleavage of ENaC at the cell surface
and the sodium transport response.
Engineered Elastase Inhibitor EPI-hNE4 Specifically Inhibits
Human hNE, and Not Trypsin, Stimulation of hENaC—To
determine whether EPI-hNE4 was capable of inhibiting hNE-
mediated stimulation of hENaC, we used the Xenopus oocyte
expression system to overexpress hENaC proteins by injecting
, , and  hENaC subunit cRNAs. Xenopus oocytes injected
with hENaCwere exposed to hNE for 2 min, and INa was meas-
ured using the two-electrode voltage clamp system. Exposure of
theXenopus oocytes to hNE inMBS solution resulted in a3.5-
fold increase in INa over untreated oocytes (Fig. 1, lane 2 versus
lane 1). This stimulation of hENaC (lane 2) was significantly
inhibited in oocytes exposed to hNE in the presence of the ela-
stase inhibitor EPI-hNE4 (lane 3), suggesting that the catalytic
activity of hNE is involved in the activation of ENaC. Trypsin
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stimulated INa in hENaC-injected oocytes 5.5-fold over non-
treated oocytes (lane 4), but EPI-hNE4 did not inhibit trypsin-
induced activation of hENaC (lane 5), demonstrating the spec-
ificity of the inhibitor for elastase. Thus, both hNE and trypsin
activate ENaC. To determine whether the activation pathways
for these proteases were similar, hENaC-injected oocytes were
exposed to trypsin alone (lane 4) or to hNE and trypsin together
(lane 6). Simultaneous exposure to hNE and trypsin resulted in
a 5-fold increase in INa (lane 6), but no additive effect was
observed (compare lanes 6 versus 4 and 6 versus 2). This non-
additive stimulation of INa in hENaC-injected oocytes by hNE
and trypsin suggests that each protease can achieve maximum
proteolytic stimulation of ENaC, either through proteolytic
cleavage of the channel itself or through one of its regulatory
proteins. The possibility that the expression system was trans-
lationally saturated was ruled out by injecting ten times more
ENaC cRNAs, leading to a 10-fold increase in INa (lane 7).
EPI-hNE4 Does Not Inhibit Amiloride-sensitive Na Trans-
port Induced by Co-injected Prostasin—Channel-activating
proteases (CAPs) are membrane-bound serine proteases (12)
known to be expressed and to regulate ENaC in the lung (13–
15). To determine whether EPI-hNE4 was capable of inhibiting
exogenously expressed membrane proteases, hENaC-injected
oocytes were co-injected with human CAP-1 (prostasin) (Fig.
2), a serine protease known to be expressed in airway epithelia
and known to increase amiloride-sensitive INa. Oocytes co-in-
jected with hCAP-1 and hENaC significantly increased INa
(3-fold) (lane 2) over hENaC-injected oocytes (lane 1). Increas-
ing concentrations of EPI-hNE4 added at the time of cRNA
injection (lanes 3–5) were unable to significantly decrease the
CAP-1-induced increase in INa. This further indicated that EPI-
hNE4 is specific for hNE and does not affect human CAP-1
(prostasin) activity. As shown previously, the protease inhibitor
aprotinin (added at the time of cRNA injection) was able to
significantly decrease the prostasin-mediated increase in INa
(lane 6), indicating that inhibition of CAP-1-mediated stimula-
tion was effective. EPI-hNE4 had no significant effect on amilo-
ride-sensitive INa when applied in the absence of hNE (lane 7).
Aprotinin had no significant effect on basal currents (lane 8).
NE Cleaves  rENaC, but Not  and  rENaC, and Is Specif-
ically Inhibited by EPI-hNE4—Recently, Hughey et al. (25) have
shown that ENaC is proteolytically processed. It was demon-
strated that cell surface-expressed ENaC proteins are cleaved
and that cleavage correlated with channel activity. This sug-
gested that intracellular proteolytic cleavage was involved in
channel maturation (25). The mechanism of extracellular pro-
tease stimulation of ENaC activity has not been identified. We
wished to determinewhether extracellular stimulation of ENaC
by hNEwas correlatedwith direct cleavage of the channel at the
cell surface.
Exposure of rENaC-injected Xenopus oocytes to hNE
increased amiloride-sensitive Na current (INa)7.5-fold (p
0.001, n  13) within 2 min. This stimulation of rENaC by hNE
was significantly inhibited (p  0.001) when the elastase inhib-
itor EPI-hNE4 was present in the MBS solution. To determine
whether hNE activation was mediated by direct cleavage of the
cell surface-expressed protein, cell surface biotinylation was
performed. Xenopus oocytes injected with rENaC and exposed
briefly (2 min) to hNE alone or to hNE and EPI-hNE4 together
were biotinylated to separate membrane and intracellular pro-
teins. Biotinylated and non-biotinylated V5-tagged  rENaC
coinjected with  and  rENaC was separated on a 8–15% gra-
dient PAGE, transferred to a nitrocellulose membrane for
Western blotting, and probed with V5 antibody (Fig. 3B). Con-
trol oocytes as well as those exposed to hNE, and hNE4 in the
presence of EPI-hNE4 (lanes 1–3, respectively), had a major
band at 95 kDa as well as 80- and 65-kDa fragments corre-
FIGURE 1. Engineered elastase inhibitor EPI-hNE4 specifically inhibits
hNE, and not trypsin, stimulation of hENaC. Oocytes were injected with
 hENaC cRNAs 24 h before experimental analyses. Oocytes were exposed
to hNE (100 g/ml), trypsin (10 g/ml), and an hNE inhibitor EPI-hNE4 (44
g/ml) for 2 min at room temperature before INa was measured by voltage
clamp technique. Shown is relative (relative to untreated ENaC-injected
oocytes with INa of 2.7  0.6 A) mean  S.E. of three independent experi-
ments performed with six oocytes/experimental condition). ***, p  0.001
versus lane 1; *, p  0.05 versus lane 1; ##, p  0.01 versus lane 2 by Student’s t
test.
FIGURE 2. EPI-hNE4 does not inhibit amiloride-sensitive Na transport
induced by co-injected hCAP1. Co-expression of  hENaC with hCAP1
caused increased INa (lane 2), which was not inhibited by EPI-hNE4 (lanes 3–5,
concentration indicated; p  0.05, lanes 2–5 versus lane 1 (control)) but was
inhibited by 100 g/ml aprotinin (lane 6, #, p  0.05 versus lane 2). Shown is
relative (relative to untreated ENaC-injected oocytes with INa of 3.1  0.8 A)
mean  S.E. of four independent experiments performed with five oocytes/
experimental condition.
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sponding to the full-length  ENaCmolecule, and two cleavage
products. The non-biotinylated protein pool (Fig. 3C) also con-
tained the 95-kDa full-length  ENaCmolecule, but not the 80-
and 65-kDa fragments (lanes 1–3). These products were ENaC
specific and not observed in water-injected oocytes (lane 4).
Absence of actin in the biotinylated cell surface proteins and its
presence in the non-biotinylated protein pool confirmed that
the biotinylation reaction did not label intracellular proteins.
This result indicated that  ENaC was not cleaved by hNE but
was cleaved by endogenous proteases. The corresponding
amiloride-sensitive INa currents are shown in panel A showing
a 5-fold increase of INa after 2min of incubation in the presence
of elastase, an effect fully inhibited by the inhibitor.
V5-tagged  rENaC coinjected with  and  ENaC was also
Western blotted and probed with V5 antibody.  ENaC was
expressed as a single band of 105 kDa at the cell surface (Fig. 4B,
lanes 1–3) as well as in the non-biotinylated protein pool (Fig.
4C, lanes 1–3) in all ENaC-injected conditions. These products
were ENaC specific and not observed in water-injected oocytes
(lane 4). This result indicated that  ENaC was not cleaved by
hNE or by intracellular proteases. The corresponding amilo-
ride-sensitive INa currents are shown in panel A showing a
5-fold increase of INa after 2 min of incubation in the presence
of elastase, an effect fully inhibited by the inhibitor.
V5-tagged  rENaC coinjected with  and  rENaC was
also Western blotted and probed with V5 antibody. Control
oocytes as well as those exposed to hNE and hNE4 in the
presence of EPI-hNE4 (Fig. 5B, lanes 1–3, respectively)
exhibited a band of 87 kDa as well as a 76-kDa fragment,
corresponding to the full-length  ENaC molecule and the
endogenous cleavage product, respectively. In addition, the
hNE-treated oocytes exhibited an additional fragment of 67
kDa (Fig. 5B, lane 2, *) that was not present when oocytes were
exposed to hNE in the presence of EPI-hNE4 (lane 3). The non-
biotinylated protein pool (Fig. 5C) similarly contained the
87-kDa full-lengthENaCmolecule, aswell as the 76-kDa frag-
ment, but not the 67-kDa fragment in all ENaC-injected condi-
tions (lanes 1–3). These products were ENaC specific and not
observed in water-injected oocytes (lane 4). This result indi-
cated that  ENaC was cleaved by endogenous proteases and
further cleaved by hNE at the cell surface. The corresponding
amiloride-sensitive INa currents are shown in panel A showing
a 6-fold increase of INa after 2min of incubation in the presence
of elastase, an effect fully inhibited by the inhibitor.
Western blot densitometry was performed (Molecular
Imager FX; Bio-Rad) to quantify the appearance of the hNE-
induced 67-kDa  rENaC fragment at the cell surface (Fig. 6A)
and in the non-biotinylated total pool (Fig. 6B). Band densities
of five independent Western blots were normalized to full-
length 87-kDa  ENaC in untreated oocytes (Fig. 6, A and B,
lanes 1). Biotinylated cell surface 87-kDa  ENaC band density
was not significantly altered by exposure to hNE alone or when
co-incubated with its inhibitor EPI-hNE4 (Fig. 6A, lanes 2 and
3). Cell surface 76-kDa  ENaCwas similarly not affected (lanes
FIGURE 3. hNE does not cleave cell surface-expressed  ENaC. Wild-type
 and  rENaC were co-injected with V5-tagged  rENaC in Xenopus laevis
oocytes. A, amiloride-sensitive current was measured in untreated
oocytes (3.1  1.3 A, lane 1), oocytes exposed to 10 g/ml hNE (lane 2),
10 g/ml hNE in the presence of EPI-hNE4 (lane 3), and non-injected
oocytes (lane 4) in five independent experiments. hNE significantly acti-
vated ENaC (*, p  0.05), and this activation was inhibited by EPI-hNE4
(#, p  0.05). Cell surface-biotinylated proteins (surface) and non-biotiny-
lated proteins (total pool) were probed with V5 antibody to detect the V5
tag inserted in the C terminus of  ENaC. B, biotinylated cell surface pro-
teins. Full-length 95-kDa  ENaC as well as 80- and 65-kDa fragments were
expressed at the cell surface in ENaC-injected oocytes (lanes 1–3). Treat-
ment with hNE did not produce any additional cleavage products (lane 2).
C, non-biotinylated protein pool. The non-biotinylated protein pool con-
tained full-length 95-kDa  ENaC in ENaC-injected oocytes (lanes 1–3).
Absence of actin in the biotinylated proteins indicated that no non-bio-
tinylated proteins were labeled. Even quantities of actin in the non-bio-
tinylated proteins indicated even protein loading.
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4–6). The hNE-induced 67-kDa fragment was significantly
increased by hNE treatment (lane 8, *, p  0.05) over untreated
controls (lane 7). The appearance of the hNE-induced 67-kDa
fragment was prevented by inhibiting hNE with EPI-hNE4
(lane 8 versus lane 7, #, p  0.05).
The non-biotinylated total pool 87- and 76-kDa  rENaC
band densities were not significantly affected by treatment with
hNE nor hNE with EPI-hNE4 (Fig. 6B, lanes 1–6). The 67-kDa
 rENaC band was not detected in the non-biotinylated total
pool protein (lanes 7–9). These results indicated that the hNE-
induced 67-kDa  rENaC cleavage product was significantly
increased relative to non-hNE treated controls and that inhibi-
tion of hNE by EPI-hNE4 prevented the formation of this cleav-
age product. The presence of the 67-kDa  rENaC cleavage
product at the cell surface and not in the non-biotinylated total
protein pool indicated that hNE was acting uniquely on cell
surface-expressed  rENaC and not on the intracellular 
rENaC proteins.
DISCUSSION
Elastase-induced ENaC Activation and Cleavage at the Cell
Surface: Evidence for Specific Exogenous Proteolysis—Recent
evidence clearly indicates that ENaC activation can be directly
induced by exposingmembrane patches to external trypsin (17)
or elastase (17). The effect is rapid, characterized by a large
change in ENaCopenprobability (Po).Obviously, this approach
does not allow the correlation of ENaC activitywith proteolysis.
In the present study, we took advantage of the very rapid
ENaC activation (within 2 min) by external application of hNE,
which can then be correlated with the pattern of proteolysis at
the cell surface in the same oocytes. A short time course (2min)
minimizes the problem of endo- or exocytosis so that mainly
the pool of ENaC molecules pre-existing at the plasma mem-
brane are studied.Weused a highly specific elastase inhibitor to
definitively assign induced functional and biochemical events
to elastase catalytic activity. Using this protocol we have dem-
onstrated that the  ENaC subunit undergoes a cleavage that is
cell surface specific (within 2min), because it is not observed in
the intracellular pool. The induced fragment is 67 kDa, (Fig.
5, *). Cell surface cleavage was efficiently prevented by the ela-
stase inhibitor EPI-hNE4. It is therefore tempting to speculate
that this cell surface-specific cleaved formofENaC represents
the activation of “near silent” channels observed in membrane
patches. In otherwords, the change inPomay not only correlate
with, but be caused by, proteolysis. How could cleaving a chan-
nel increase its Po? This is not so unlikely if one considers the
number of biological processes, e.g. prohormones (i.e. insulin),
the coagulation cascade, that are activated by cleavage. Serine
proteases (trypsin, chymotrypsin) secreted as inactive pro-en-
zymes and activated into zymogens by intramolecular cleavage
are other well known examples. A similar scheme could also
apply to an ionic channel, such as ENaC. ENaC is characterized
by its unusual gating kinetics, with postulated transitions from
different modes, i.e. from low Po (i.e.“near silent”, Po  0.05) to
FIGURE 4. hNE does not cleave cell surface-expressed  ENaC. Wild-type
 and  rENaC were co-injected with V5-tagged  rENaC in X. laevis
oocytes. A, amiloride-sensitive current was measured in untreated
oocytes (2.7  1.3 A, lane 1), oocytes exposed to 10 g/ml hNE (lane 2),
10 g/ml hNE in the presence of EPI-hNE4 (lane 3), and non-injected
oocytes (lane 4) in five independent experiments. hNE significantly acti-
vated ENaC (*, p  0.05), and this activation was inhibited by EPI-hNE4
(#, p  0.05). Cell surface-biotinylated proteins (surface) and non-biotiny-
lated proteins (total pool) were probed with V5 antibody to detect the V5
tag inserted in the C terminus of  ENaC. B, biotinylated cell surface pro-
teins. Full-length 105-kDa  ENaC was expressed at the cell surface in
ENaC-injected oocytes (lanes 1–3). Treatment with hNE did not produce
any additional cleavage products (lane 2). C, non-biotinylated protein
pool. The non-biotinylated protein pool contained the full-length  ENaC
in ENaC-injected oocytes (lanes 1–3). Absence of actin in the biotinylated
proteins indicated that no non-biotinylated proteins were labeled. Even
quantities of actin in the non-biotinylated proteins indicated even protein
loading.
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high Po gating modes (Po  0.8) (1). These different gating
modes could correspond to the cleavage of  ENaC. Impor-
tantly, the  subunit is insensitive to both endogenous and
exogenous proteolysis (Fig. 4). We have no explanation for this
resistance. One can, however, speculate that the N-glycosyla-
tion of the subunitmight play a role because the subunit has
FIGURE 5. hNE cleaves cell surface-expressed  ENaC. Wild-type  and 
rENaC were co-injected with V5-tagged  rENaC in X. laevis oocytes.
A, amiloride-sensitive current was measured in untreated oocytes (3.0 
0.9 A, lane 1), oocytes exposed to 10 g/ml hNE (lane 2), 10 g/ml hNE in
the presence of EPI-hNE4 (lane 3), and non-injected oocytes (lane 4) in five
independent experiments. hNE significantly activated ENaC (*, p  0.05),
and this activation was inhibited by EPI-hNE4 (#, p  0.05). Cell surface-
biotinylated proteins (surface) and non-biotinylated proteins (total pool)
were probed with V5 antibody to detect the V5 tag inserted in the C
terminus of  ENaC (lanes 1– 4). B, biotinylated cell surface proteins. Full-
length 87-kDa  ENaC as well as the 76-kDa fragment were expressed at
the cell surface in ENaC-injected oocytes (lanes 1–3). Treatment with hNE
resulted in an additional  ENaC cleavage product (*, lane 2) relative to the
non-treated ENaC-injected oocytes (lane 1). The appearance of this addi-
tional band was prevented when oocytes were treated with the hNE inhib-
itor EPI-hNE4 and hNE, simultaneously (lane 3). C, non-biotinylated pro-
tein pool. The non-biotinylated protein pool contained the full-length
87-kDs  ENaC and the 76-kDa endogenous cleavage product (lanes 1–3).
Absence of actin in the biotinylated proteins indicated that no intracellu-
lar proteins were labeled. Even quantities of actin in the intracellular pro-
teins indicated even protein loading.
FIGURE 6. Western blot densitometry of  ENaC. Western blots of biotiny-
lated and non-biotinylated V5-tagged  ENaC were analyzed using a Bio-Rad
densitometer in five independent experiments. A, cell surface-biotinylated 
ENaC band intensity was normalized to the 87-kDa  ENaC band in untreated
ENaC-injected oocytes (lane 1). Neither hNE treatment (lane 2) nor treatment
with hNE and EPI-hNE4 (lane 3) significantly affected the quantity of 87-kDa 
ENaC at the cell surface. The 76-kDa  ENaC fragment was expressed at the
cell surface in ENaC-injected oocytes (4 – 6). Neither treatment with hNE (lane
5) nor with hNE and EPI-hNE4 (lane 6) changed the intensity of the 76-kDa 
ENaC fragment significantly. There was a significant increase in the intensity
of the 67-kDa  ENaC fragment when oocytes were treated with hNE (lane
8, * denotes p  0.05), but this band was not present in untreated oocytes
(lane 7) or in oocytes treated with hNE in the presence of EPI-hNE4 (lane 9).
B, non-biotinylated  ENaC band intensity was normalized to the 87-kDa 
ENaC band in untreated ENaC-injected oocytes (lane 1). Neither hNE treat-
ment (lane 2) nor treatment with hNE and EPI-hNE4 (lane 3) significantly
affected the quantity of 87-kDa  ENaC in the non-biotinylated ENaC-
injected oocytes. The endogenously cleaved 76-kDa  ENaC fragment was
present in the non-biotinylated ENaC-injected oocytes (4 – 6). Neither
treatment with hNE (lane 5) nor with hNE and EPI-hNE4 (lane 6) changed the
intensity of the 76-kDa  ENaC fragment significantly. The 67-kDa  ENaC
band was not present in the non-biotinylated proteins (lanes 7–9).
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no less than 12 N-glycosylation sites. This could protect the
proteolytic cleavage sites fromenzyme access to their substrate.
In addition, it is worth noting that the primary sequence of the
 subunit does not have any consensus sequences for cleavage
by furin. Therefore, differences in primary sequence and pro-
tein folding/maturation may explain the striking difference
between the  and  subunits.
Interestingly, the  ENaC subunit undergoes endogenous
cleavage producing an 80-kDa fragment and a 65-kDa fragment
at the cell surface (Fig. 3A). These cleavage products are not
seen in the non-biotinylated intracellular pool (Fig. 3B) as an
abundant form of the channel. However, overexposure of the
Western blot reveals that these fragments are present intracel-
lularly in low quantities relative to the full-length 95-kDa 
ENaC (data not shown). Taken together these data indicate that
 ENaC is endogenously processed late in its maturation, con-
sistent with a furin cleavage profile, which occurs in the late
Golgi or at the cell surface.
Our Western blots of  ENaC indicate that hNE is unable
to further cleave this subunit. However, in a small percent-
age (6%) of ourWestern blots cleavage of the  ENaC subunit
is observed upon exposure to hNE. This is, however, incon-
sistent with the activation of INa by hNE that is observed in
all experiments irrespective of the hNE-specific cleavage of 
ENaC. This is in contrast to the hNE-induced 67-kDa 
ENaC cleavage product that is observed to correlate 100%
with induction of INa.
Physiological and Pathophysiological Implications of Serine
Proteases and Serine Protease Inhibitors—Our findings are rel-
evant to the development of novel drug therapies for patients
suffering from CF. In this disease, mucociliary clearance is
severely decreased. Mucociliary clearance is critically depend-
ent on the control of the periciliar liquid (PCL). Combined
defects of accelerated Na transport and the failure to secrete
Cl deplete the PCL compartment, abrogating both cilia-de-
pendent and cough clearance. Subsequent to PCL depletion,
mucus adheres to airway surfaces and persistent mucin secre-
tion generates the formation of “thickened”mucus plaques and
plugs, which become the nidus for bacterial infection (10). This
pathogenic scheme has been validated by the generation of a
mouse model overexpressing the  ENaC subunit in distal air-
ways that led to a PCL depletion and CF lung phenotype mim-
icking the human disease (11). In this setting, ENaC becomes a
valid target for the treatment of CF lung disease. The inhibition
of ENaC by amiloride has already been shown to be effective in
increasing mucociliary clearance (27). Similar beneficial effects
can be observed by inhalation of hypertonic saline, producing a
sustained acceleration of mucus clearance and improved lung
function (26). Inhibition of elastase by the specific inhibitor
would have dual and synergistic effects on CF airways: blocking
ENaC activity, thereby repleting PCL and improving mucocili-
ary clearance, and blocking the effect of elastase on tissue
inflammation and destruction. This inhibitor would have the
advantage of not interfering with the physiological control of
ENaC by endogenous lung serine proteases, such as prostasin
or other membrane-bound serine proteases, expressed in air-
way epithelia (15).
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